Alopecia areata is an autoimmune condition that causes hair to fall out in small, round patches, most often on the scalp. It affects roughly 2% of the population at some point in their lives, and while it occurs in both sexes, women often experience a greater emotional and social burden because of cultural expectations around hair. The condition is not caused by stress alone, is not contagious, and does not leave permanent scars on the skin.
Why the Immune System Attacks Hair Follicles
Hair follicles normally enjoy a kind of protected status in the body, shielded from the immune system in what researchers call “immune privilege.” In alopecia areata, that protection breaks down. Once it does, immune cells, primarily a type of white blood cell called CD8+ T cells, swarm around the follicle in a pattern pathologists describe as a “swarm of bees” under the microscope. These cells recognize proteins in the hair follicle as foreign threats and mount an attack.
The inflammatory cycle is self-reinforcing. Interferon-gamma, a signaling molecule released by those immune cells, triggers even more immune activity through a feedback loop involving additional inflammatory signals. This loop keeps the inflammation going, which is why patches of hair loss can persist for months or years without treatment. It’s also why newer therapies target this specific signaling pathway (more on that below).
What Hair Loss Looks Like in Women
The most common presentation is one or more smooth, coin-sized bald patches on the scalp. The skin in these areas looks normal, with no redness, scaling, or scarring. Women may also lose hair from their eyebrows, eyelashes, or body, sometimes in combination with scalp patches. In rarer cases, the loss follows an unusual pattern: a band along the hairline (called ophiasis) or a linear streak that can cross the scalp, brow, and lash line on one side of the face.
Some women notice short, broken hairs at the edges of a patch. These are sometimes called “exclamation mark hairs” because they’re narrow at the base and wider at the tip, like an inverted exclamation point. They’re one of the hallmark signs dermatologists look for. Other clues visible under magnification include tiny black dots (hairs broken off at the surface), yellow dots (follicles plugged with oil and skin cells), and fine, wispy regrowth hairs that may curl tightly before falling out again.
Alopecia areata exists on a spectrum. Most women have patchy loss affecting a small portion of the scalp. A smaller number progress to alopecia totalis, which is complete scalp hair loss, or alopecia universalis, which involves loss of all body hair. Nails can also be affected, showing pitting, ridges, or roughness, though many women with alopecia areata have completely normal nails.
How It Differs From Other Female Hair Loss
Women searching for answers about hair loss often wonder whether they’re dealing with alopecia areata or the more common female pattern hair loss (androgenetic alopecia). The distinction is usually straightforward. Female pattern hair loss causes gradual, diffuse thinning across the top of the scalp, often widening the part line over months or years. Alopecia areata produces distinct, well-defined bald patches that can appear within days or weeks. The scalp skin in those patches is smooth and bare, not thinning.
Telogen effluvium, another common cause of hair loss in women, typically follows a trigger like childbirth, surgery, illness, or severe stress. It causes widespread shedding rather than patches. Postpartum hair loss in particular is temporary and usually resolves on its own within several months.
Diagnosis
Most dermatologists can diagnose alopecia areata by examining the scalp, often with a dermatoscope, a handheld magnifying device with built-in lighting. The combination of exclamation mark hairs, black dots, and yellow dots is distinctive enough to confirm the diagnosis in the majority of cases. When the presentation is ambiguous, a small scalp biopsy can show the characteristic immune cell infiltrate around hair follicles.
Because alopecia areata clusters with other autoimmune conditions, your dermatologist may also check thyroid function. Thyroid disorders, particularly hypothyroidism, are the most common associated condition, appearing in roughly 18% of people with alopecia areata in clinical studies. Other conditions that show up more often than expected include vitiligo, atopic dermatitis (eczema), and lupus.
Treatment for Patchy Hair Loss
For women with limited patches, corticosteroid injections directly into the affected area remain the most widely used first-line treatment. The injections are given every four to six weeks, typically using a very fine needle. Results vary by study, but regrowth rates are encouraging for localized disease: in one study, 92% of patients with patchy alopecia areata showed some regrowth by six weeks. Other research found that roughly 60 to 67% of treated patients achieved substantial regrowth (more than 75% coverage) within 12 weeks, depending on the concentration used.
The injections can sting, and repeated treatments sometimes cause temporary thinning of the skin at the injection site. For women who prefer to avoid needles, topical corticosteroids or other immune-modulating agents applied directly to the scalp are an alternative, though they tend to work more slowly and are generally less effective for larger patches.
JAK Inhibitors for Extensive Hair Loss
The treatment landscape shifted significantly starting in 2022 with the approval of a new class of oral medications called JAK inhibitors. These drugs work by interrupting the specific inflammatory signaling loop that drives the immune attack on hair follicles. Three are now FDA-approved for alopecia areata:
- Baricitinib (approved 2022): 35 to 40% of patients in clinical trials achieved at least 80% scalp coverage by 36 weeks.
- Ritlecitinib (approved 2023, for ages 12 and up): 32% reached the same threshold by 24 weeks.
- Deuruxolitinib (approved 2024): 41% achieved at least 80% scalp coverage by 24 weeks.
These medications represent a meaningful advance for women with extensive or total hair loss, a group that previously had few reliable options. They are oral pills taken daily and require ongoing use to maintain results, since the underlying autoimmune tendency does not go away. Side effects and monitoring requirements vary by medication, so these are typically prescribed after a thorough discussion with a dermatologist.
Chances of Hair Growing Back on Its Own
Older estimates suggest that 34 to 50% of people with alopecia areata experience spontaneous regrowth within the first year. That number sounds reassuring, but a recent systematic review looking specifically at placebo groups in clinical trials painted a more cautious picture. Among untreated patients with moderate to severe disease, only about 8% showed meaningful improvement, and virtually none achieved near-complete regrowth. The takeaway: mild, limited patches have a reasonable chance of resolving without treatment, but more extensive loss rarely reverses on its own.
When hair does regrow, it often comes in white or very fine at first, gradually returning to its normal color and texture over months. Recurrence is common. Many women experience cycles of loss and regrowth over years, though the pattern is unpredictable.
Emotional and Psychological Effects
Hair loss carries significant emotional weight for women, and the unpredictable nature of alopecia areata adds to the strain. In a study of 75 patients, 67% met criteria for depression and 73% for anxiety. The majority of cases were mild, and none were severe, but even mild, persistent distress affects daily life, social confidence, and self-image. Women with visible patches may avoid social situations, change hairstyles frequently, or feel pressure to explain their appearance to others.
Support groups, both online and in person, can help. So can working with a therapist who has experience with chronic medical conditions. Many women also find practical relief in cosmetic solutions like scalp micropigmentation, wigs, toppers, and eyebrow microblading while waiting for treatment to take effect or during periods of active loss.